Technology:

The innovation in our products lies in the unique synthesis of particle production, coating methodologies, drug targets and novel indications. There are no approved drugs for common and severe diseases of the inner ear such as presbycusis, and there are no intracochlear drug delivery systems available for the treatment of any inner ear disease. The development of such formulations could have a dramatic effect.

Pipeline:

Drug: OR-102A for the treatment of Autoimmune Inner Ear Disease

Drug: OR-102C for the prevention of residual hearing loss during cochlear implant surgerical implantation

Drug: OR-112 for the prevention of age related hearing loss

Drug: OR-404IT for the treatment of otitis